169131-66-2Relevant academic research and scientific papers
Bradykinin receptor antagonists containing N-substituted amino acids: In vitro and in vivo B2 and B1 receptor antagonist activity
Goodfellow, Val S.,Marathe, Manoj V.,Kuhlman, Karen G.,Fitzpatrick, Timothy D.,Cuadrado, David,Hanson, Wendy,Zuzack, John S.,Ross, Sherman E.,Wieczorek, Maciej,Burkard, Michael,Whalley, Eric T.
, p. 1472 - 1484 (1996)
We report a systematic probing of the structural requirements of the bradykinin (BK) type 2 (B2) receptor for antagonist activity by incorporating N-alkyl-amino acid residues at positions 7 and 8 of a potent antagonist sequence. Compound 1 (D-A
Processes for the Preparation of Ribociclib and Intermediates Thereof
-
Paragraph 0196-1098, (2019/11/22)
The present invention provides processes for the preparation of Ribociclib, as well as intermediates useful in the preparation thereof. In particular, processes are provided for the preparation of a compound of Formula (4), and its conversion to Ribocicli
BRADYKININ ANTAGONIST PEPTIDES INCORPORATING N-SUBSTITUTED GLYCINES
-
, (2008/06/13)
The present invention provides bradykinin type peptides containing N-substituted glycines, particularly bradykinin antagonist peptides useful for the treatment of conditions mediated by bradykinin including pain and inflammation.
